Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023172

Enrollment

Unknown

Registered

2019-05-15

Start date

2016-02-01

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

Case series:bortezomib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria in the International Mylema Working Group (IMWG), confirmed by bone marrow analysis, X-ray film, blood image analysis and laboratory examination; (2) In accordance with international standards Staging system (ISS), Durier-Salmon staging system (DS) staging criteria [22]; (3) newly diagnosed patients; (4) receiving more than 3 courses of regular chemotherapy; (5) The expected survival period is more than 3 months.

Exclusion criteria

Exclusion criteria: (1) with severe heart, liver, kidney, lung or blood system diseases; (2) secondary plasma cell enlargement; (3) primary disease worse and organ failure; (4) data missed or loss of follow-up.

Design outcomes

Primary

Measure	Time frame
heat shock protein 27;	—

Countries

China

Contacts

Public ContactJing Li

Rizhao People's Hospital

liudoctor123@hotmail.com+86 18663372657

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026